Aktienanalyse zu Resmed Inc (RMD)RMDResmed Inc

ResMed Inc. is a holding company. The Company, through its subsidiaries, in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease, neuromuscular disease and other chronic diseases. Its segments include Sleep and Breathing Health segment and the Residential Care Software segment. It also operates a Software as a Service (SaaS) business in the United States and Germany that includes out-of-hospital software platforms designed to support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. Its products and solutions are designed to improve patients' quality of life and reduce the impact of chronic disease. Its cloud-based digital health software applications, along with its devices, are designed to provide connected care. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

ResMed Inc (RMD) is a good buy right now due to its current price of $230.05, which is below the analyst price target of $262 from RBC Capital, indicating a potential upside of 14%. Additionally, the company's gross margin stands at 58.12%, showcasing strong profitability. However, a risk to consider is the recent insider selling, where the CEO sold nearly 5,000 shares, which could signal concerns about the company's future performance.

10 analysts cover RMD: 4 rate it Buy, 2 Hold and 4 Sell. The average price target is 294.00.